The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in ...

Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent observational study found.

Adults in Tanzania living with HIV and taking tenofovir have a higher rate of chronic kidney disease vs. those without the ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25. If approved, FILSPARI could be the first and only approv ...

For individuals with type 1 diabetes, intraindividual body weight variability, or body weight cycling, is associated with an ...

The National Institute for Nephrology Dialysis and Transplantation (NINDT) has planned a series of events to mark this ...

Denmark: A recent study published in the Journal of Diabetes and its Complications has explored the role of kidney fat ...